Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CE330
- Development stage
- Preclinical
- Lead developer
- Cello Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
CE330 is an investigational protein vaccine currently in preclinical development by Cello Therapeutics. The candidate is developed using the company's proprietary Cellular Nanoparticle (CNP) platform technology, which involves coating therapeutic cores with natural cell membranes to improve biocompatibility and targeted delivery. While specific molecular targets and indications for CE330 have not been publicly disclosed, the program is part of a broader pipeline focused on leveraging the CNP platform for cancer immunotherapy and the treatment of solid tumors.
Beyond the preview
Go deeper on CE330.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CE330.